---
title: "Volitionrx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286463768.md"
datetime: "2026-05-14T20:30:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286463768.md)
  - [en](https://longbridge.com/en/news/286463768.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286463768.md)
---

# Volitionrx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1 M

Revenue: As of FY2026 Q1, the actual value is USD 1 M, beating the estimate of USD 409.92 K.

#### Revenue

Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025.

#### Operating Loss

Operating loss was down 3% for the quarter versus the comparable quarter in 2025.

#### Net Cash Used in Operating Activities

Net cash used in operating activities was $5.3 million.

#### Receipts

Receipts in the quarter included $5.4 million in net proceeds from equity sales through VolitionRx Limited’s at-the-market facility. Additionally, $1.9 million in net proceeds was received from the issuance of a convertible note and warrant, and $1 million of non-dilutive funding was received from agencies of the Walloon Region.

#### Outlook / Guidance

VolitionRx Limited expects a $5 million contractual milestone payment upon publication of its Nu.Q® Vet feline prototype assay’s clinical manuscript and anticipates an additional approximate $0.9 million in funding from the Walloon Region over the next 12 months based on milestones. The company is actively working on the reimbursement submission for Nu.Q® Lung Cancer and is engaged in discussions with diagnostic and liquid biopsy companies to secure licensing agreements for upfront milestone payments, royalties, and recurring revenue. These efforts underscore VolitionRx Limited’s focus on advancing its product pillars and securing strategic partnerships and future revenue streams.

### Related Stocks

- [VNRX.US](https://longbridge.com/en/quote/VNRX.US.md)

## Related News & Research

- [VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update | VNRX Stock News](https://longbridge.com/en/news/286460343.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [ProShare Advisors LLC Purchases 257,762 Shares of Cintas Corporation $CTAS](https://longbridge.com/en/news/286893600.md)
- [Norfolk Southern Stock Outlook: Is Wall Street Bullish or Bearish?](https://longbridge.com/en/news/287239015.md)
- [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md)